Notice2024-16096
Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Survey on Quantitative Claims in Direct-to-Consumer Prescription Drug Advertising
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
July 23, 2024
Issuing agencies
Health and Human Services DepartmentFood and Drug Administration
Abstract
The Food and Drug Administration (FDA or Agency) is announcing that a collection of information entitled "Electronic Records: Electronic Signatures" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (PRA).
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 141 (Tuesday, July 23, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 141 (Tuesday, July 23, 2024)]
[Notices]
[Page 59742]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-16096]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2023-N-0795]
Agency Information Collection Activities; Announcement of Office
of Management and Budget Approval; Survey on Quantitative Claims in
Direct-to-Consumer Prescription Drug Advertising
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
that a collection of information entitled ``Electronic Records:
Electronic Signatures'' has been approved by the Office of Management
and Budget (OMB) under the Paperwork Reduction Act of 1995 (PRA).
FOR FURTHER INFORMATION CONTACT: Amber Sanford, Office of Operations,
Food and Drug Administration, Three White Flint North, 10A-12M, 11601
Landsdown St., North Bethesda, MD 20852, 301-796-8867,
<a href="/cdn-cgi/l/email-protection#d484869587a0b5b2b294b2b0b5fabcbca7fab3bba2"><span class="__cf_email__" data-cfemail="b9e9ebf8eacdd8dfdff9dfddd897d1d1ca97ded6cf">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: On December 21, 2023, the Agency submitted a
proposed collection of information entitled ``Survey on Quantitative
Claims in Direct-to-Consumer Prescription Drug Advertising'' to OMB for
review and clearance under 44 U.S.C. 3507. An Agency may not conduct or
sponsor, and a person is not required to respond to, a collection of
information unless it displays a currently valid OMB control number.
OMB has now approved the information collection and has assigned OMB
control number 0910-0929. The approval expires on June 30, 2027. A copy
of the supporting statement for this information collection is
available on the internet at <a href="https://www.reginfo.gov/public/do/PRAMain">https://www.reginfo.gov/public/do/PRAMain</a>.
Dated: July 17, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024-16096 Filed 7-22-24; 8:45 am]
BILLING CODE 4164-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on July 23, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.